Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Age \> 18 years of age
Histologically confirmed carcinoma of the prostate
High-intermediate risk or high risk as defined by NCCN criteria:
High intermediate: 2 or 4 intermediate risk factors (T2B-T2C, Gleason GG 2 or 3, PSA 10-20) or GG 3 or intermediate risk with equal or \>50% biopsy core involvement
High-risk: one of T3a, Gleason GG 4 or 5, or PSA \>20 ng/ml
Very-high risk: one of primary Gleason Pattern 5, \>4 cores Grade Group 4 or 5, clinical T3b, or more than 1 high-risk feature
Conventional imaging (bone scan and abdominal pelvic computed tomography) negative for extra-pelvic nodal, skeletal or visceral metastases
Willing to give informed consent to participate in this clinical trial
Able and willing to complete EPIC questionnaires
You may not be if
Prior prostate cancer treatment (apart from prior 5-alpha reductase inhibitor treatment); androgen deprivation therapy prior to enrollment or treatment planning not permitted
Men with clinical T4 disease are excluded
Contraindication to radical prostate radiotherapy e.g. connective tissue disease or inflammatory bowel disease
Contraindication to prostate MRI (i.e. non0compatible stent, pacemaker, prosthesis, etc.)
Contraindication to use of PSMA PET agent PSMA 1007 due to intolerance or allergy
Anticoagulation medication (if unsafe to discontinue for gold seed insertion)
Diagnosis of bleeding diathesis
Poor baseline urinary function defined as a score of 5 ("big problem") on question 5 of the EPIC 26 (Overall, how big a problem has your urinary function been for you during the last 4 weeks?)
Definitive extra-pelvic nodal or distant metastatic disease on conventional staging investigations
Clareo Health | PSMA MRI Guided Prostate SBRT (ARGOS)/Comprehensive, Longitudinal Evaluation of Imaging Biomarkers Post Radiotherapy (CLIMBER)
